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ABSTRACT 
BACKGROUND: Hereditary peripheral neuropathies are inherited disorders affecting the peripheral 
nervous system, including Charcot-Marie-Tooth disease, familial amyloid polyneuropathy and 
hereditary sensory and motor neuropathies. While the molecular basis of hereditary peripheral 
neuropathies has been extensively researched, interventional trials of pharmacological therapies are 
lacking.  
OBJECTIVE: We collated evidence for the effectiveness of pharmacological and gene-based treatments 
for hereditary peripheral neuropathies.  
METHODS: We searched several databases for randomised controlled trials (RCT), observational 
studies and case reports of therapies in hereditary peripheral neuropathies. Two investigators 
extracted and analysed the data independently, assessing study quality using the Oxford Centre for 
Evidence Based Medicine 2011 Levels of Evidence in conjunction with the Jadad scale.  
RESULTS: Of the 2043 studies initially identified, 116 trials met our inclusion criteria, of which only 36 
were carried over into our final analysis. Ascorbic acid was shown to have no therapeutic benefit in 
CMT1A, while a combination of baclofen, naltrexone and sorbitol (PXT3003) shows some efficacy but 
phase III data are incomplete. In TTR-related amyloid polyneuropathy tafamidis, patisiran, inotersen 
and revusiran showed significant benefit in high quality RCTs. Smaller studies showed the efficacy of 
L-serine for SPTLC1-related hereditary sensory neuropathy, riboflavin for Brown-Vialetto-Van Laere 
syndrome (SLC52A2/3) and phytanic acid-poor diet in Refsum disease (PHYH). 
CONCLUSIONS: The ‘treatable’ variants highlighted in this project will be flagged in the treatabolome 
database to alert clinicians at the time of the diagnosis and enable timely treatment of patients with 
hereditary peripheral neuropathies.    
INTRODUCTION 
Rare diseases (RD) are individually rare but collectively common, affecting 6-8% of the global 
population [1]. Their rarity poses unique problems to clinicians and their patients, resulting in 
significant delays in both diagnosis and treatment. One problem is that clinicians dealing with the 
relevant patients are largely unaware or unable to keep up with the increasing evidence base 
associated with these conditions. Considering that approximately 72% of rare disease cases are caused 
by Mendelian genetic variants [2], an ability to accurately and quickly inform clinicians of existing gene 
and variant-specific therapeutics would represent a quantum leap in clinical care. The ‘treatabolome’ 
project aims to systematically collate and evaluate evidence for the effectiveness of rare disease 
treatments to provide a database of ‘treatable’ variants. Currently, as part of the multi-national ‘Solve-
RD’ project, several expert-led teams across the rare disease community are working towards building 
that database. This knowledgebase will be integrated into an interoperable rare disease genomics 
platform to facilitate clinicians’ access to the latest clinical data and enable timely treatment of rare 
disease patients. The first element of this project has been completed and published for congenital 
myasthenic syndromes [3], and a standardised protocol to be applied across the different arms of the 
treatabolome project has been submitted. We now aim to undertake an element of this project to 
define the treatabolome of hereditary peripheral neuropathies.  
Hereditary peripheral neuropathies are a group of inherited disorders affecting the peripheral nervous 
system. These are divided into four major subgroups: hereditary sensory and motor neuropathies, 
distal hereditary motor neuropathies, hereditary sensory and autonomic neuropathies and more 
complex hereditary neuropathies. The most common form is the hereditary sensory and motor 
neuropathy, also known as Charcot-Marie-Tooth disease (CMT) , with a prevalence of around 1/2500 
[4, 5]. CMT can be further subdivided into demyelinating and axonal forms, depending on their 
pathophysiology. In demyelinating forms, myelin sheath degeneration precedes axon degeneration, 
whereas axon degeneration is the primary pathology in axonal forms. 
As of January 2020, 93 genes have been identified to cause CMT [6]. These genes cover a wide range 
of molecular functions and intracellular processes, which can be broadly categorised as affecting 
intracellular transport in the axon, organelle dynamics and protein synthesis (axonal CMT), and cellular 
processes causing disruption of myelin production or organisation (demyelinating CMT). Inheritance 
patterns include all modes of Mendelian inheritance, maternal inheritance (mitochondrial DNA 
variants) and more complex patterns. 
All CMT-related disorders are characterised by a length-dependent degeneration of the peripheral 
neurons and differ by the groups of neurons affected, with CMT affecting both sensory and motor 
neurons. Motor symptoms include weakness, atrophy or deformity, and sensory symptoms include 
numbness, paraesthesia or pain [7]. Some may involve the autonomic nervous system, resulting in 
features like impaired sweating, postural hypotension or insensitivity to pain [7]. Patients may also 
present with other neurological symptoms (e.g. spastic paraparesis, ataxia, cranial nerve 
abnormalities) and have non-neurological features (e.g. cataract, scoliosis, cardiac symptoms). It is 
important to note that the phenotype may be overlapping across the disease subgroups [5].  
The disease typically follows a slowly progressive course. The prognosis of individuals depends on their 
genotype, but it is modified by other so far unknown genetic, epigenetic and environmental factors 
[8]. Curative pharmacological treatment is currently only available for some subtypes of hereditary 
peripheral neuropathies, but supportive management is useful in all cases. Supportive treatments 
involve physical therapy, occupational therapy, genetic counselling, orthotics (splints, braces, walking 
aids) and surgery [9]. 
METHODS 
The systematic review was designed using Cochrane Collaboration methodology [10], as guided by the 
treatabolome project principles for generating FAIR-compliant datasets (soon to be published). Studies 
of randomised and non-randomised controlled trials, observational studies, case series and case 
reports of pharmacological treatment for patients with genetically confirmed hereditary peripheral 
neuropathies were considered for inclusion in the full systematic review. Reviews including systematic 
and expert reviews were screened for relevant primary data not included in our original search. All 
appropriate outcome measures clearly indicating a positive, neutral or negative (toxic) response to 
treatment were considered, including change in measures of muscle strength, functional ability and 
clinical examination results. Studies were assessed for quality using the Oxford Centre for Evidence-
Based Medicine (OCEBM) 2011 Levels of Evidence [11] in conjunction with the Jadad scale [12]. All 
steps were carried out by two investigators (A.L. and M.J.) independently and reviewed by the expert 
team lead (R.H.), with regular meetings to establish consensus.  
Inclusion criteria 
The condition studied was genetically confirmed hereditary peripheral neuropathy. We considered 
only studies involving patients with genetically confirmed mutations in known neuropathy genes.  
Hereditary peripheral neuropathies diagnosed by techniques other than formal genetic testing were 
excluded due to the phenotypic overlap between the different types of neuropathies, which could 
confound clinical or electrophysiological diagnoses. Participants with any level of severity, age of onset 
and level of penetrance of phenotypic features were included. Pharmacological therapies or genotype-
related dietary changes specifically targeting the neuropathy were included in this study. Non-
pharmacological interventions such as physiotherapy, surgery and genetic counselling were excluded.  
Literature and trial database search  
Several electronic databases were searched in order to cover all available evidence regarding 
pharmacological treatment for hereditary peripheral neuropathies. Firstly, to discover studies of the 
highest OCEBM evidence levels, we searched for randomised controlled trials and systematic reviews 
of genetic neuropathies using the Cochrane Central Register of Controlled Trials (CENTRAL), The 
Cochrane Neuromuscular Disease Group Specialized Register, ClinicalTrials.gov, European Clinical 
Trials Database (EudraCT), WHO International Clinical Trials Registry (ICTRP) and the Centre for 
Reviews and Dissemination (CRD) database. Secondly, we carried out a wider search using the PubMed 
database, intending to capture a greater range of relevant literature. Full details of search terms and 
filters used for each database can be seen in the Supplementary Table 1. Database specific filters were 
applied to ensure only interventional studies with results available were included, and that major 
“miss-hit” diseases (e.g. Guillain-Barré syndrome) were excluded. Additionally, a filter for publication 
date after 01/01/1991 was applied where necessary, as causative genes for inherited peripheral 
neuropathies were discovered after this date [13, 14]. 
Data selection 
Studies identified from each database were compiled and screened for duplicates. Our inclusion 
criteria progressively determined studies (1) written in English, with (2) human patients, who were (3) 
genetically diagnosed with (4) hereditary peripheral neuropathy, involving a (5) pharmacological 
intervention and which (6) declare their results. Additionally, relevant articles were extracted from the 
reference sections of systematic or expert reviews and screened for possible inclusion as above.  
Data extraction and analysis  
Characteristics of each study that fulfilled our inclusion criteria were captured in a standardised data 
extraction table (Supplementary Table 2). Information was collected on participants (number of 
participants, phenotype, age, affected gene and variant), interventions (type, dose, delivery, frequency 
and duration of treatment) and both molecular (biomarker) and clinical (functional) outcome 
measures. 
The quality of each study was assessed using both the OCEBM 2011 Levels of Evidence and the Jadad 
scale, to accommodate for smaller yet higher quality studies commonly seen in rare disease research. 
Data extraction was carried out by A.L. and M.J., prior to second assessment by R.H. As the OCEBM 
and Jadad scores incorporate risk of bias in their scoring, we did not carry out a formal risk of bias 
assessment. We must assume a high risk of bias for all non-randomised studies, and the OCEBM and 
Jadad scores are correspondingly low.  
RESULTS 
Our search identified 2043 potentially relevant entries across all databases (Figure 1.). Following 
duplicate analysis with manual confirmation and elimination of duplicates, 1892 individual studies 
remained. The titles and abstracts of these studies were then screened for inclusion using the stated 
inclusion criteria in progressive steps (see Data Selection). 116 studies met all the criteria on initial 
screening, whereas 1776 studies failed to satisfy at least one aspect of the criteria (Figure 1). Next, 
studies which passed this stage were read in full by 2 assessors to confirm their suitability according to 
the criteria, excluding a further 86 studies. The characteristics and findings of these studies were 
recorded in full in Supplementary Table 2. At this stage, systematic reviews and expert reviews 
included in our search were examined for any additional primary data that was missed. Then, the 
expert team lead (R.H.) reviewed the remaining 116 studies and excluded 86 studies on study-specific 
grounds (explained below), while 35 studies remained for detailed analysis. Additionally, 1 study which 
was not included in the original dataset was flagged for inclusion (Foley et al., 2014), giving a total of 
36 included studies. The final studies are presented as grouped by the causative genes involved (Tables 
1-3). For studies involving more than two different gene mutations, all described mutations are listed 
in Supplementary Table 3.  
Of all included studies (n=36) the largest two genetic groups were amyloid neuropathy caused by 
mutations in the TTR gene (n=16) and CMT1A, due to the duplication of PMP22 (n=9) respectively. 
Numbers of studies were much fewer for other genotypes. Four studies looked at HSAN due to 
mutations in ELP1 (n=2), SPTLC1 (n=1) and SPTLC2 (n=1). Two studies examined Brown-Vialetto-Van 
Laere Syndrome caused by mutation in SLC52A2 (n=1) or SLC52A3 (n=1). The genes MT-ATP6 (n=1) and 
SCN9A (n=1) each had 1 study. The remaining studies looked at neuropathies due to metabolic causes 
associated with mutations in PHYH (Refsum disease, n=2). 
Randomised controlled clinical trials 
We identified 18 randomised controlled trials (RCTs). The most investigated treatment was oral 
ascorbic acid for CMT1A, with 6 independent studies. The studies varied in dose between 1.5g and 4g 
per day, for either 1 or 2 years. Most studies used the Charcot-Marie-Tooth Neuropathy Score (CMTNS) 
[15] as the primary outcome measure, with the possible addition of muscle strength, sensory or nerve 
conduction studies. However, none resulted in a statistically significant clinical improvement. Likewise, 
measurements of target effect (e.g. PMP22 mRNA levels) showed no changes on treatment with 
ascorbic acid. On quality assessment, all ascorbic acid RCTs were scored at 5 according to the Jadad 
criteria, indicating that these were well designed and properly reported studies. Two studies 
investigated the use of PTX3003, a combination therapy of baclofen, naltrexone and sorbitol, to treat 
CMT1A. These were large phase II and III studies, both scoring 5 by Jadad criteria. The phase II study 
showed no change in Overall Neuropathy Limitation Scale (ONLS) [15] in the group treated with low 
doses, but a modest improvement in the highest dose group. This result prompted further 
investigation of the treatment in a phase III study. However, inconsistencies were found in the stability 
of the high dose formulations in the phase III study, which led to early termination of this arm of the 
study. Despite this, there was a small, significant improvement in neuropathy severity (ONLS) prior to 
termination. We conclude that although there is some evidence that PTX3003 is effective in CMT1A, 
doubts remain about the validity of the incomplete data from this study. 
We identified 6 RCTs with four different compounds (tafamidis, diflunisal, patisiran, inotersen) which 
showed positive results in ATTR-familial amyloid polyneuropathy [16]. Two of these investigated the 
treatment of the common c.148G>A, p.Val50Met (previously called p.Val30Met) variant with 
tafamidis, a TTR stabiliser drug preventing TTR protein complex dissociation and thereby inhibiting 
amyloid formation [17, 18]. Both studies used 20mg oral tafamidis daily for 18 months. The larger of 
these studies (n=128) [17] did not show a significant improvement in the primary endpoints of 
Neuropathy Impairment Score in the Lower Limbs (NIS-LL) or Total Quality of life (TQOL), although 
some improvement was shown in neurological impairment (evidenced by reduced muscle weakness 
overall, specifically at the distal muscle sites). The smaller study (n=63), however, did show a significant 
improvement in NIS-LL [18]. One other study in 130 patients treated over 2 years with diflunisal, a non-
steroid anti-inflammatory drug which has been shown to stabilise TTR, reduced the rate of progression 
of neurological impairment and preserved quality of life compared to placebo [19]. 
The third study (APOLLO) examined the effect of patisiran, a double-stranded synthetic ribonucleic 
acid molecule (RNAi) that targets mutant and wild type TTR, after 18 months treatment in patients 
carrying the c.148G>A (p.Val50Met) (~50% of patients) or other TTR mutations [20, 21]. There was an 
improvement detected by the modified Neuropathy Impairment Score (mNIS+7).  
Inotersen, a single-stranded deoxynucleotide analogue (DNA) complementary to TTR pre-mRNA has 
also been implemented to silence TTR in a 15-month multi-centre RCT (NEURO-TTR) in 172 patients 
with TTR-related peripheral neuropathy, of which approximately 50% had the p.Val50Met mutation 
[22]. This trial met both of its primary endpoints, as there was significantly less decline in the 
neuropathy and quality of life measures in the inotersen group compared with the placebo group.  
Two studies looked at treatment options in hereditary sensory and autonomic neuropathies (HSAN). 
Treatment with L-serine in 18 patients with SPTLC1 variants resulted in significant decrease in CMTNS 
scores compared to placebo. Additionally, there was a corresponding decrease in deoxysphinganine 
levels, confirming target effect. 
Non-randomised trials 
We identified 5 non-randomised trials, all of which were open-label extensions of RCTs in patients with 
TTR-related neuropathy treated with patisiran, tafamidis and revusiran. These resulted in useful data 
on the long-term impact of these treatments. The APOLLO phase II trial showed a significant 
improvement in neuropathy in p.Val50Met patients following treatment with patisiran for 24 months 
[23], and formed the basis for the APOLLO phase III RCT, which gives better evidence of the efficacy of 
patisiran. Another trial (Pfizer) investigated the use of tafamidis in the non-p.Val50Met subpopulation 
of patients  and demonstrated TTR stabilisation, but it did not investigate changes in the neuropathy 
phenotype [24]. Revusiran treatment (Alnylam Pharmceuticals) was administered in patients who had 
previously received liver transplants, but the study was terminated due to increased mortality rate in 
the treated patients [25], similar to another study in TTR-related cardiomyopathy [26] . The increased 
mortality was unlikely to be related to the treatment, but rather the effect of studying an older and 
more severely affected patient population. 
Case series 
Fourteen case studies or case series were identified, all of which included only a few or single patients. 
These represented incidental findings on patients with unusual presentations or reported on 
treatments already established to be effective in larger studies (Tables 1-3).  However, there were 
several interesting examples of seemingly effective genotype-specific targeted treatments of the 
molecular defect, which should be considered in patients with causative mutations in these genes. One 
case study highlighted a positive effect of riboflavin in a single patient with Brown-Vialetto-Van-Laere 
syndrome (BVVL) due to mutations in the riboflavin transporter (SLC52A2/3). An additional study 
investigating riboflavin treatment for BVVL was flagged up by R.H. for inclusion [27]. This publication 
was not detected in our original search as it did not include search terms ‘genetic’ or ‘inherited’ in the 
title or abstract.  High dose riboflavin was shown to have a positive effect on neurological symptoms 
in both SLC52A2 and SLC52A3 genotypes, and early treatment of these patients may prevent 
neurological deterioration [27].  
Other targeted treatments with positive results include low phytanic acid diet in Refsum disease, an 
inborn error of metabolism in which high phytanic acid results in neurological symptoms [28, 29], and 
a case study with L-serine in a patient with HSAN due to SPTLC2 mutation decreased deoxysphinganine 
levels [30].   
Several case studies were not included in Tables 1-3 due to case-specific reasons given below, as 
decided by the expert team lead (R.H.). Four case studies investigating immune therapies were 
excluded, as they were thought to be treating secondary immune-mediated neuropathies rather than 
the primary hereditary neuropathy and were therefore not gene specific. Furthermore, these 
treatments may even be harmful in hereditary neuropathies. Another case study of potential benefit 
was reported in a patient with neuropathy caused by docosahexaenoic acid (DHA) deficiency, which 
was treated with cod liver oil (high levels of DHA), however the causative mutation was not identified 
[31]. Four other studies were excluded on the basis of treating non-gene specific symptoms of 
neuropathies, such as foot deformity in CMT1A and CMT4A, erectile dysfunction in TTR and fatigue in 
CMT1A. One uncontrolled trial investigating algasidase alfa in Fabry disease and another study on 
treatment with betain, folinic acid, B12 and B6 vitamins to restore the folate pathway in MTHFR 
mutations were excluded because these are complex diseases and cannot be listed as a specific 
neuropathy treatment.  
Distribution and relationships of Jadad and OCEBM scores 
Both Jadad and OCEBM scores aim to give an estimate of the scientific credit of a study, illustrated by 
a very high degree of correlation between the two scores (Figure 3B), with 34/47 studies belonging to 
2 clusters of studies. Studies with low OCEBM (<2) and high Jadad (5) are well conducted RCTs, while 
studies with high OCEBM (4) and low Jadad (0) represent case studies or case series lacking most of 
the desired features of a good clinical trial.  
DISCUSSION 
We performed a systematic review to evaluate the evidence for pharmacological and gene-based 
treatments in inherited peripheral neuropathies. Our original search identified 1892 independent 
publications, of which 36 were included in our final analysis. The evidence for the efficacy of the 
studied treatments was weighted based on the quality of the clinical trials or case studies. We 
identified 15 treatments, which should be initiated in patients with some genetic forms of inherited 
neuropathies. 
However, our study has some limitations. Firstly, we may have missed some papers reporting positive 
effect of a treatment as part of a larger study on novel disease genes or describing large cohorts of 
diverse patients. However, search terms including these would have produced many times more 
results, thereby precluding careful consideration of studies. The future inclusion of machine-readable 
variant-level genotype information in clinical trial registration and reporting would improve data 
collation in the rare disease field. 
Indeed, we had to add one paper based on our expertise in inherited neuropathies on riboflavin-
responsive neuropathy (BVVL) [27, 30]. Secondly, although there are supporting data on the rationale 
and efficacy of some of these treatments, the degree of evidence is not satisfactory in many studies. 
The reasons include insufficient study design, inappropriate outcome measures, low number of 
participants and short study duration. Our review highlights these limitations and demonstrates that 
we must improve our standards in planning clinical trials. Careful consideration of study size and 
duration, number of participants, appropriate outcome measures and international collaboration 
(multi-centre studies) are essential to improve the development of treatments in inherited 
neuropathies. Thirdly, many studies did not give gene and variant data of study participants in 
sufficient detail, which meant they were of limited use to our study. Lastly, this database needs regular 
updating in the future, as the number of clinical trials and relevant case studies are steadily increasing 
in inherited peripheral neuropathies. This is a time intensive process and requires a dedicated expert 
team. 
Most evidence has been gathered in CMT1A. Ascorbic acid has been extensively researched and 
proven to be ineffective in this disease subtype. More recently, a combination of baclofen, naltrexone 
and sorbitol (PXT3003) has shown significant improvement in CMT scores (CMTNS and ONLS) and may 
be a strong candidate for pharmacotherapy in the future. However, these results must first be 
confirmed in the phase III trial currently ongoing [1]. Therefore, based on the evidence presented in 
this review, no definitive recommendations can be made for first-line treatment at present. 
In TTR-related amyloid neuropathy, four treatments (tafamidis, patisiran, inotersen and diflunisal) 
showed significant benefit in high quality RCTs and should be initiated in patients with pathogenic 
variants in TTR. These drugs have been approved in many different countries for treatment of TTR-
related neuropathy. There are still uncertainties about what the long-term clinical benefits are, when 
to initiate treatment and how to incorporate these treatments into the current algorithms. The choice 
of treatment and time of commencement needs careful consideration in specialised centres [16], and 
is influenced by national regulatory and licensing guidelines [32]. Early diagnosis of this condition is 
essential for timely access to treatment. The availability of gene silencing treatments raises issues 
regarding genetic screening and management of asymptomatic individuals.  
In other forms of CMT and metabolic neuropathies, treatment recommendations are based on a 
slightly weaker evidence base of case studies and smaller trials. A positive effect of L-serine 
supplementation in patients with HSAN due to mutations in SPTLC1 (and potentially SPTLC2) is 
emerging, and we highlighted the efficacy of targeted dietary supplementation and restriction in a few 
other rare genetic neuropathies (BVVL, Refsum and methylenetetrahydrofolate reductase deficiency). 
Therefore, if pathogenic mutations are identified in these genes, targeted treatments should be 
considered in clinical practice.  
We detected an increase in the number of publications in recent years (Figure 2B), although this 
increase was still driven mainly by case studies and case series. Well-designed RCTs were performed 
mostly in CMT1A and in amyloid neuropathy caused by TTR mutations (figure 2B). When plotting study 
size against clinical outcome (figure 3B), we observed that RCTs with the largest patient enrolments 
(n>100) were more likely to demonstrate efficacy in TTR amyloid neuropathy or conclude lack of 
benefit in CMT1A. This reflects the greater statistical power of larger studies as compared to smaller 
studies. Case studies and small case series are more likely to report a clinical improvement, but this 
may be based on unsatisfactory evidence. For example, there is often reporting bias as unusual patient 
presentations are more likely to be reported. However, some case studies targeting the molecular 
defect in rare metabolic conditions should be applied to treat specific genetic neuropathies even 
without performing RCTs.  
Although the number of effective treatments in inherited peripheral neuropathies is still very limited, 
the availability of large international patient cohorts, better outcome measures and more accurate 
natural history data will facilitate the development of further effective therapies. The recent 
identification of new genetic forms of CMT has launched research into developing novel therapies, 
which may in the future be added to the treatabolome database. Since the completion of our search, 
the discovery of mutations in SORD has unveiled how existing aldose reductase inhibitors have great 
potential to treat this common type of CMT [33]. Based on in vitro studies in patient-derived fibroblasts 
and in Drosophila, aldose reductase inhibitors normalized intracellular sorbitol levels and also 
ameliorated motor and eye phenotypes. These findings will form the basis for future clinical trials in 
patients with this form of CMT. Further progress is being made due to the technological advancements 
in molecular genetics, allowing scientists to generate diverse animal models that closely resemble the 
CMT phenotype. Additionally, it is now possible to culture patient-derived neurons in a dish using 
cellular reprogramming and differentiation techniques [34]. 
There is an ever-increasing need for data sharing in rare genetic diseases. This need is beginning to be 
met by the establishment and implementation of several large databases, which integrate next 
generation sequencing data with clinical phenotyping data (e.g. RD-CONNECT, DECIPHER, GENESIS, 
etc). These databases contain information on several thousands of patients and their family members, 
as well as being easily accessible to clinicians analysing their patients’ samples. On average, each 
human genome has approximately 30,000 variants compared to the standard assembly, which may be 
benign or pathogenic. For this reason, appropriate filtering for rare, causative variants and linking the 
available phenotypic information (HPO terms in RD-CONNECT) results in a higher diagnostic rate. 
Furthermore, to enable rapid translation from diagnosis to treatment, variants in the genes highlighted 
as part of the treatabolome project will be flagged in RD-CONNECT. This data will be immediately 
reported back to the clinician, together with the genetic diagnosis as determined by exome 
sequencing. Our work will allow this streamlined solution to be made available to clinicians dealing 
with inherited peripheral neuropathy patients. This approach facilitates clinicians’ access to the latest 
clinical data relevant to the genotype of their patients and enables timely treatment, ultimately leading 
to improved prognosis and a better quality of life of rare disease patients. The treatabolome project 
therefore offers a powerful tool, with significant advantages for both clinicians and patients with 
inherited peripheral neuropathies.  
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 Table 1. Summary of results in Charcot-Marie-Tooth type 1A (CMT1A). 
  
Gene, 
Mutation 
Title First Author, 
Journal (Year) 
Phenotype 
target HPO 
term(s) 
Study 
type 
Number of 
patients 
Drug name Duration Target effect  
(+/-/=),  description 
Clinical effect  
(+/-/=), description 
JADAD 
score 
(1-5) 
OCEBM 
score 
(1-5) 
UK 
License 
(Y/N) 
PMP22, 
dup 
Ascorbic acid for CMT type 1A in children: a 
randomised, double-blind, placebo-controlled, 
safety and efficacy trial 
Burns, Lancet 
Neurol (2009) [29] 
Abnormal nerve 
conduction 
velocity 
RCT 81 (42 
intervention, 39 
placebo) 
Ascorbic acid 1 year + ↑plasma ascorbic 
acid concentration  
= No significant 
change in median 
NCV, strength, 
function, or QoL 
5 2 *N   
PMP22, 
dup 
Effect of ascorbic acid in patients with CMT type 
1A: a multicentre, randomised, double-blind, 
placebo-controlled trial 
Micallef, Lancet 
Neurol (2009)[35] 
Muscle 
weakness, Distal 
sensory 
impairment  
RCT 179 (intervention 
61 dose 3g, 56 
dose 1g, 62 
placebo) 
Ascorbic acid 1 year 
 
Not described =  No significant 
change in CMTNS 
5 2 *N   
PMP22, 
dup 
Oral high dose ascorbic acid treatment for one 
year in young CMT1A patients: a randomised, 
double-blind, placebo-controlled phase II trial 
Verhamme, BMC 
Med (2009) [36] 
Muscle 
weakness, Distal 
sensory 
impairment  
RCT 13 (6 intervention, 
7 placebo) 
Ascorbic acid 1 year  
 
Not described = No significant 
change in median 
NCVs, strength, 
sensation, CMTNS or 
disability  
5 2 *N   
PMP22, 
dup 
Randomised controlled trial with ascorbic acid in 
CMT type 1A: results of the CMT-TRIAAL/CMT-
TRAUK 
Ascorbic Acid in Charcot-Marie-Tooth Disease 
Type 1A (CMT-TRIAAL and CMT-TRAUK): A 
Double-Blind Randomised Trial 
Pareyson, JPNS 
(2011) 
 
Pareyson, Lancet 
neurol (2011) [35] 
Muscle 
weakness, Distal 
sensory 
impairment  
RCT 277 (138 
intervention, 133 
placebo) 
Ascorbic acid 24 
months 
 Not described =  No significant 
change in CMTNS 
5 2 *N  
 
PMP22 
dup 
High-dosage ascorbic acid treatment in CMT type 
1A: results of a randomized, double-masked, 
controlled trial 
Lewis, JAMA Neurol 
(2013) [36]  
Muscle 
weakness, Distal 
sensory 
impairment  
RCT 85 (69 
intervention, 16 
placebo) 
Ascorbic acid 2 years =  No change in PMP22 
mRNA levels 
= No significant 
change in CMTNS  
5 2 *N  
 
PMP22, 
dup 
Phase II, Randomized, Placebo-controlled Trial in 
Patients With CMT type 1A 
ClinicalTrials.gov 
Identifier: 
NCT01401257 
(2017) [37] 
Muscle 
weakness, Distal 
sensory 
impairment  
RCT 80 PXT3003  
 
12 
months 
 Not described + Decreased CMTNS & 
ONLS in high dose 
group 
5 2 N  
PMP22, 
dup 
A multicenter, double-blind, placebo controlled, 
pivotal phase III study (PLEOCMT) of a fixed 
combination of baclofen, naltrexone and sorbitol 
(PXT3003), for the treatment of CMT1A 
Attarian, Muscle & 
nerve (2017) 
NCT02579759 
(2020) [38] 
Muscle 
weakness, Distal 
sensory 
impairment  
RCT 323 PXT3003  15 
months 
 Not described +
/
=  
Significant ↓ONLS 
for dose 2, non-
significant ↓ONLS 
for dose 1 
5 2 N 
PMP22, 
dup 
Effects of exercise and creatine on myosin heavy 
chain isoform composition in patients with 
Charcot-Marie-Tooth disease 
Smith, Muscle Nerve 
(2006) [39] 
Muscle 
weakness  
RCT 18 Creatine 
monohydrate + 
resistance 
training 
12 weeks  +  Significant decrease 
in MHC type I 
+  ↓Chair-rise-time, 
↑muscle strength 
5 2 N 
 Gene, Mutation 
(RefSeq) 
(*see Supplement 
3 for other 
mutations) 
Title First Author, 
Journal 
(Year) 
Phenotype target 
HPO term(s) 
Study type Number of 
Patients 
Drug name Duration Target effect (+/-
/=) & description 
Clinical effect (+/-/=) & description JADAD 
score  
(1-5) 
OCEBM 
score  
(1-5) 
UK 
License 
(Y/N) 
TTR, 
c.148G>A, 
p.Val50Met 
(NM_000371.3)  
+*21 other 
mutations 
Repurposing diflunisal for familial amyloid 
polyneuropathy: a randomized clinical trial 
Berk, JAMA 
(2013) [19]   
Muscle weakness, 
Distal sensory 
impairment 
RCT 130 
(71 V30M, 
59 other 
mutations) 
Diflunisal  
 
2 years 
 
 Not 
described 
+  ↑NIS+7, ↓Progression of 
neuropathy, 
↑QoL (↓SF-36 physical, 
↑SF-36 mental) 
1 2 *N  
TTR, 
c.148G>A, 
p.Val50Met 
(NM_000371.3) 
 
Tafamidis for Transthyretin Familial Amyloid 
Polyneuropathy: A Randomized, Controlled 
Trial 
 
Coelho,  
Neurology 
(2012) [17] 
Muscle weakness, 
sensory 
impairment 
RCT 128 Tafamidis 
 
18 
months 
+  TTR 
stabilisatio
n 
=/+ No change in NIS-LL or  total 
QoL, ↓progression 
neuropathy 
5 2 Y  
TTR, 
c.148G>A, 
p.Val50Met 
(NM_000371.3) 
+*8 other 
mutations 
Long-term safety and efficacy of tafamidis 
for the treatment of hereditary transthyretin 
amyloid polyneuropathy: results up to 6 
years 
 
Barroso,  
Amyloid 
(2017) [40] 
 
Muscle weakness, 
Distal sensory 
impairment 
Open label 
extension 
study  
 
93 (75 
V30M + 18 
non-V30M)  
 
Tafamidis 
 
6 years  Not 
described 
=/+  Significant delay neuropathy 
progression 
1 3 Y  
TTR, 
c.224T>C, 
p.Leu75Pro  
(NM_000371.3) 
Effects of liver transplantation and tafamidis 
in hereditary transthyretin amyloidosis 
caused by transthyretin Leu55Pro mutation: 
a case report 
Kon, Amyloid 
(2015) [41] 
 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
Case study 
 
1 Tafamidis 1 year   Not 
described 
=/+  ↓Progression of 
polyneuropathy & cardiac 
amyloidosis  
0 4 Y  
TTR, 
c.148G>A, 
p.Val30Met  
(NM_000371.3) 
+*8 other 
mutations 
Monitoring effectiveness and safety of 
Tafamidis in transthyretin amyloidosis in 
Italy: a longitudinal multicenter study in a 
non-endemic area 
 
Cortese,  
J Neurol 
(2016)[42] 
 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
Cohort 
study  
 
61 Tafamidis  3 years  Not 
described 
=/+  No effect in V30M, 
↓neuropathy progression in 
non-V30M & high disability 
1 3 Y  
TTR, 
c.173A>C, 
p.Asp58Ala 
(NM_000371.3) 
Tafamidis for the Treatment of Hereditary 
Transthyretin Amyloid Cardiomyopathy: A 
Case Report 
 
Fujita,  
Cardiology 
(2017) [43] 
 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
Case study 
 
1 Tafamidis 
meglumine 
 
2 years  Not 
described 
=/-  No change in nerve 
conduction (axonopathy), 
progression of amyloid 
cardiomyopathy 
0 4 Y  
TTR,  
c.290C>A, 
p.Ser97Tyr 
(NM_000371.3) 
+ *13 other 
mutations  
The Effects of Fx-1006A on Transthyretin 
Stabilization and Clinical Outcome Measures 
in Patients with Non-V30M Transthyretin 
Amyloidosis 
EudraCT 
number: 
2007-006791-
12 (2016) [24] 
 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
Open label 
study 
21 Tafamidis 43-76 
years 
+  TTR 
stabilisatio
n 
N/A  1 3 *N 
TTR, 
c.401A>G, 
p.Tyr134Cys 
(NM_000371.3) 
Transthyretin-related hereditary amyloidosis 
in an Argentinian family with TTR Tyr114Cys 
mutation 
M. A. Aguirre, 
Amyloid 
(2017) [44] 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
Case study 1 Tafamidis 65 years  Not 
described 
N/A  Discontinued due to adverse 
effects  
0 4 Y 
 Table 2. Summary of results in Transthyretin Familial amyloid polyneuropathy (TTR-FAP).  
TTR, 
c.148G>A, 
p.Val30Met  
(NM_000371.3) 
 
Safety and Efficacy of Orally Administered Fx-
1006A in Patients with Familial Amyloid 
Polyneuropathy (FAP): a Phase II/III, 
Randomised, Double-Blind, Placebo-
Controlled Study 
EudraCT 
number: 
2006-002792-
41 (2009) [18] 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
RCT 63 Tafamidis 25-74 
years 
 Not 
described 
+ ↓change from baseline NSLL 
LSMean score  
3 2 Y 
TTR 
(V30M and 
others) 
The Effect Of Tafamidis For The Transthyretin 
Amyloid Polyneuropathy Patients With 
V30M Or Non-V30M Transthyretin 
Clinicaltrials.g
ov Identifier: 
NCT01435655 
(2015) 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
RCT 10 Tafamidis  20-75 
years 
 Not 
described 
= No observable change in 
clinical outcomes 
0 4 Y 
TTR, 
c.148G>A, 
p.Val30Met  
(NM_000371.3)  
 + *38 other 
mutations 
APOLLO: A Phase 3 Multicenter, 
Multinational, Randomized, Double-blind, 
Placebo-controlled Study to Evaluate the 
Efficacy and Safety of Patisiran (ALN-TTR02) 
in Transthyretin (TTR)-Mediated 
Polyneuropathy (Familial Amyloidotic 
Polyneuropathy-FAP) 
+ Patisiran, an RNAi Therapeutic, for 
Hereditary Transthyretin Amyloidosis 
EudraCT 
number: 
2013-002987-
17 (2017)[21] 
 
Adams,  
Neurology 
(2018) [20] 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
RCT 77 Patisiran 24-83 
years 
+  ↓serum 
TTR 
+  ↓change from baseline in 
mNIS+7 neuropathy score, 
↓change from baseline in 
Norfolk QOL-DN score 
5 2 Y 
TTR 
(Not described)  
A Phase 2, Multicenter, Open-Label, 
Extension Study to Evaluate the Long-Term 
Safety, Clinical Activity, and 
Pharmacokinetics of ALN-TTR02 in Patients 
With Familial Amyloidotic Polyneuropathy 
Who Have Previously Received ALN-TTR02 
EudraCT 
number: 
2013-001644-
65 (2017) [23] 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
RCT 27 Patisiran 18-84 
years 
+  92% 
decrease in 
serum TTR 
+ Significant improvement in 
neuropathy  
1 3 Y 
TTR  
(Not described) 
An Open-Label Study To Evaluate The 
Efficacy And Safety Of Revusiran In Patients 
With Transthyretin-Mediated Familial 
Amyloidotic Polyneuropathy With Disease 
Progression Post Orthotopic Liver Transplant 
EudraCT 
number: 
2015-002603-
29 (2018) [25] 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
RCT 12 Revusiran 18-84 
years 
 Not 
described 
N/A  Study terminated  1 3 N 
TTR, 
c.148G>A, 
p.Val30Met  
(NM_000371.3) 
+ *26 other 
mutations 
Inotersen Treatment for Patients With 
Hereditary Transthyretin Amyloidosis 
M. D. Benson, 
N Engl J Med 
(2018) [22] 
Muscle weakness, 
Distal sensory 
impairment, 
Cardiomyopathy 
RCT 172 Inotersen 18-83 
years  
+  ↓serum 
TTR 
+  ↓change from baseline in 
mNIS+7 neuropathy score, 
↓change from baseline 
Norfolk QOL-DN score 
5 2 Y 
 Table 3. Summary of results in other CMT subtypes and metabolic neuropathies.  
Gene, Mutation (Ref 
Seq) 
(*see Supplement 3 for 
other mutations) 
Descriptive 
name 
First Author, Journal 
(Year) 
Phenotype target HPO term(s) Study type 
(number of 
patients) 
Drug name Target effect (+/-/=) & 
description 
Clinical effect (+/-/=) & description JADAD 
score 
(1-5) 
OCEBM 
score 
(1-5) 
ELP1, c.2204+6T>C, 
splice site mutation 
(NM_003640.5) 
HSAN3 Norcliffe-Kaufmann, 
Neurology (2013)[45] 
Nausea & vomiting RCT (12)  Carbidopa 
 
Not described + Decreased nausea & retching 5 2 
ELP1, c.2204+6T>C, 
splice site mutation 
(NM_003640.5)  
HSAN3 Bar-Aluma, Lung 
(2018)[46] 
Functional respiratory 
abnormality 
RCT (14) Albuterol sulfate, 
Ipratropium bromide 
 Not described + Increase in FEV1 & FVC, decrease in 
airway resistance, decrease in 
airway obstruction 
5 4 
MT-ATP6, m.9185T>C, 
p.Leu220Pro 
(NC_012920.1) 
CMT2 Panosyan, Muscle 
Nerve (2017)[47] 
Episodic flaccid weakness Case series (2) Acetazolamide  Not described + Decreased frequency & severity of 
episodic weakness 
0 4 
PHYH, c.830C>A, 
p.Ala277Glu  
(NM_001037537.1) 
Refsum 
disease 
Kohlschutter, J Child 
Neurol (2012)[29] 
Muscle weakness, 
Distal sensory impairment, 
Visual impairment 
Case study (1) Phytanic acid-poor diet + 
extracorporeal lipid 
apharesis 
+ Decrease in blood 
phytanic acid levels 
+ Decrease in neurological & 
ophthalmological disease 
progression 
0 4 
PHYH, c.135-2A>G, 
splice site mutation  
(NM_006214.4) 
Refsum 
disease 
Finsterer, J Neurol Sci 
(2008)[28] 
Not described (Peripheral 
neuropathy?) 
Case study (1) Phytanic acid-poor diet 
(Chelsea diet) 
+ Slight decrease in 
blood phytanic acid 
levels 
+ Decrease in symptoms (subjective) 0 4 
SCN9A, c.2428G>A, 
p.Val810Met 
(NM_002977.3)  
Painful 
peripheral 
neuropathy  
Adi, Mol Pain 
(2018)[48] 
Distal sensory impairment, 
Pain insensitivity 
Case study (1) Carbamazepine  + Use-dependent 
channel inhibition 
+ Decrease in burning pain  0 4 
SLC52A3, c.639G>C, 
p.Tyr213Ter + c.374C>A, 
p.Thr125Asn 
(NM_001370085.1) 
BVVL Chaya, Semin Pediatr 
Neurol (2018)[30] 
Muscle weakness Case study (1) Riboflavin + Increased EGRAC & 
riboflavin levels 
+/= Slight increase in motor function 0 4 
SLC52A2, c.916G>A, 
p.Gly306Arg  
(NM_001253815.2)  
+*7 other mutations 
BVVL Foley, Brain (2014)[27] Patient I1: Muscle weakness, 
Functional respiratory 
abnormality; 
Patient E1: Same as I1 + Visual 
impairment, Hearing 
impairment 
Case series (2)  Riboflavin +  Decreased 
(normalised) 
acylcarnitine levels  
+ Patient I1: Increased motor & 
respiratory function in patient I1;  
Patient E1: Same as I1 + decreased 
visual & hearing impairment in 
patient  
1 4 
SPTLC1, N/A HSAN1 Fridman, Neurology 
(2019)[49] 
Muscle weakness, 
Distal sensory impairment 
RCT (18) L-serine + Significant decrease 
in deoxysphinganine 
levels 
+ Significant decrease in CMTNS 
compared with placebo 
5 2 
SPTLC2, c.547C>T,  
p.Arg183Trp 
(NM_004863.3) 
HSAN1C Auranen, Cold Spring 
Harb Mol Case Stud 
(2017)[50] 
Muscle weakness, 
Distal sensory impairment 
Case study (1) L-serine + Decreased 
deoxysphinganine 
levels 
= Slight increase in CMTNS score 0 4 
PMP22, c.215C>T, 
p.Ser72Leu 
(NM_000304.4) 
CMT3 Burns, Pediatr Neurol 
(2009)[51] 
Muscle weakness, Functional 
respiratory abnormality 
Case study (1) Curcumin  Not described = No change in neurophysiology, 
muscle strength, respiratory 
function, disability or QoL 
0 4 
 Figure Legends 
Figure 1. Systematic Review methodology. (A) PRISMA flowchart of studies identified under the 
search strategy, showing filtering steps to produce study database for codification of data (B) Sankey 
diagram showing numbers of studies from each source and progressive exclusion of studies according 
to inclusion criteria. 
Figure 2. Characteristics of included studies. (A) Treemap showing number of studies by mutated 
gene. (B) Percentages of study type for studies overall, and then broken down by disease type (amyloid 
TTR neuropathy, ATTR; Charcot-Marie-Tooth type 1A, CMT1A; all other studies). (C) Distribution of 
publications by year, colours indicating study types. 
Figure 3. Meta-analysis of studies. (A) Comparison of OCEBM levels with Jadad scoring, the size of 
each point indicating the number of studies at that point, colour indicating the quality defined as the 
product of these two scores (lower OCEBM with higher Jadad being the highest quality studies). (B) 
Distribution of study outcomes, stratified by patient number and labelled by study type 
Table Legends: 
Table 1. Summary of results in Charcot-Marie-Tooth type 1A (CMT1A).  Key: + positive change, - 
negative change, = no change, NCV nerve conduction velocity, RCT randomised controlled trial, CMTNS 
Charcot-Marie-Tooth Neuropathy Score, ONLS Overall Neuropathy Limitations Scale, QoL Quality of 
Life, *Licensed for other indication 
Table 2. Summary of results in Transthyretin Familial amyloid polyneuropathy (TTR-FAP). Key: + 
positive change, - negative change, = no change, NCV nerve conduction velocity, RCT randomised 
controlled trial, V30M p.Val30Met mutation, NIS-LL Neuropathy Impairment Score in the Lower Limbs, 
QoL Quality of Life, mNIS+7 modified Neuropathy Impairment Score (+7 neurophysiologic tests), SF-36 
Short Form 36 Health Survey Questionnaire. (*licensed for other indications) 
 Table 3. Summary of results in other CMT subtypes and metabolic neuropathies. Key: HSAN3 
Hereditary sensory and autonomic neuropathy type 3, CMT2 Charcot-Marie-Tooth type 2, CMT2 
Charcot-Marie-Tooth type 3, MTHFR Methylenetetrahydrofolate reductase deficiency, HNPP 
Hereditary neuropathy with liability to pressure palsies, BVVL Brown-Violetto-Van-Laare syndrome, 
HSAN1 Hereditary Sensory and Autonomic Neuropathy type 1, HSAN1C Hereditary Sensory and 
Autonomic Neuropathy type 1C, DHA Docosahexaenoic acid, + positive change, - negative change, = 
no change, NCV nerve conduction velocity, CMAP compound muscle action potential, RCT randomised 
controlled trial, V50M p.Val50Met mutation, NIS-LL Neuropathy Impairment Score in the Lower Limbs, 
QoL Quality of Life, FEV1 forced expiratory volume in 1 second, FVC forced vital capacity, eGFR 
estimated glomerular filtration rate, EGRAC erythrocyte glutathione reductase activity coefficient, 
mNIS+7 modified Neuropathy Impairment Score (+7 neurophysiologic tests), *Licensed for other 
indications 
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